Shares of Larimar Therapeutics Inc. sank to new lows Tuesday after the U.S. Food and Drug Administration extended a clinical hold on the biotechnology company's sole pipeline candidate
A break above $11 will run to $15, and a break above $15 will let it run further to test $25 again. Long term outlook will depend on it breaking these two levels. Watch $11 & $15, and if successful then watch for $25 break.